Teva's subcutaneous reslizumab misses in Phase III for eosinophilic asthma

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase III trial in 468 patients with uncontrolled asthma and elevated blood eosinophils of of

Read the full 279 word article

User Sign In